• Diagnosis of Philadelphia chromosome (Ph)-positive (by cytogenetics or fluorescent in situ hybridization \[FISH\]) or breakpoint cluster region (BCR)-ABL-positive (by polymerase chain reaction \[PCR\]) CML in chronic phase.

• Participants should have demonstrated to have failure to therapy to one FDA-approved second-generation TKI (currently bosutinib, dasatinib, and nilotinib are approved as frontline therapy), defined as per European leukemiaNet (ELN)35 or National Comprehensive Cancer Network (NCCN) recommendations:

‣ Less than complete hematologic response (CHR) at or beyond 3 months

⁃ No partial cytogenetic response at or beyond 3 months

⁃ BCR-ABL1 ≥ 10% at or beyond 3 months

• Loss of CCyR or development of mutations or other clonal chromosomal abnormalities at any time during TKI treatment

• Age \>18 years

• ECOG performance of 0-2.

• Adequate end organ function, defined as the following: total bilirubin ≤1.5x ULN (unless due to Gilbert syndrome, in which case it should be ≤3.0x ULN), SGPT ≤2.5x ULN, creatinine clearance (CrCL) ≥ 30 mL/min (Cockcroft-Gault formula).

• Participants must sign an informed consent indicating they are aware of the investigational nature of this study, in keeping with the policies of the hospital.

• Women of pregnancy potential must practice an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized:

• Prior to study enrollment, women of childbearing potential (WOCBP) must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy.

• Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential OR women who are surgically sterile.

• In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control.

• Women and men must continue birth control for the duration of the trial and at least 3 months after the last dose of study drug.

• All WOCBP MUST have a negative pregnancy test prior to first receiving investigational product.

• Participants should have discontinued therapy with bosutinib, dasatinib or nilotinib or other anti-leukemia therapy (except hydroxyurea), at least 48 hours prior to start of study therapy and recovered from any toxicity due to these therapies to at least grade 1. The use of hydroxyurea is allowed immediately prior to study entry.